대용량 비경구 의약품(LVP) 시장 보고서 : 유형별, 용량별, 용도별, 최종사용자별, 지역별(2025-2033년)

The global large volume parenteral (LVP) market size reached USD 10.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 17.0 Billion by 2033, exhibiting a growth rate (CAGR) of 5.34% during 2025-2033.

A large volume parenteral (LVP) is a single-dose injection packaged in a glass bottle or a flexible container of more than 100ml capacity after sterilization via heat. It is injected through the skin or other external boundary tissue to directly administrate the active drug substances into the blood vessels, organs, tissues, or lesions. It generally consists of an active ingredient, water-miscible or non-aqueous vehicle, and added substances like buffers, antioxidants, preservatives, surfactants, antimicrobial agents, and tonicity adjusters. Some of the commonly available LVPs around the world are peritoneal dialysis, irrigating solutions, blood derivatives, drug premixes, and contrast agents.

Large Volume Parenteral (LVP) Market Trends:

The rising prevalence of malnutrition, growing natality rate, and increasing premature births worldwide are among the key factors catalyzing the demand for LVPs to administer a large amount of nutrients in patients who are unable to take food orally. Apart from this, they are widely used in administering essential nutrients to patients undergoing treatment for esophageal obstruction, gastrointestinal (GI) diseases, cancer, and ulcer. In addition, LVPs find extensive application in heart surgery to prevent ischemic injury to the myocardium during reperfusion and the blood flow supply restriction. This, in confluence with the escalating demand for safe, fast, and effective methods of drug administration among patients undergoing surgical interventions, is contributing to the market growth. Besides this, the growing consumption of fast food across the globe has resulted in rising instances of non-communicable diseases, such as hypertension, diabetes, obesity, and other metabolic disorders. This, in turn, is positively influencing the adoption of LVPs that are a mixture of dextrose, amino acids, lipids, added electrolytes, trace metals, and vitamins.

Key Market Segmentation:

Breakup by Type:

• Soft Bag LVP
• Plastic Bottle LVP
• Glass Bottle LVP

Breakup by Volume:

• 100 ML - 250 ML
• 250 ML - 500 ML
• 500 ML - 1000 ML
• 1000 ML - 2000 ML
• 2000 ML and More

Breakup by Application:

• Therapeutic Injections
• Fluid Balance Injections
• Nutritious Injections

Breakup by End Users:

• Hospitals
• Clinics
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Albert David Ltd., B. Braun Melsungen AG, Baxter International Inc., BML Parenteral Drugs, Fresenius Kabi AG, Grifols S.A, Otsuka Pharmaceutical Co. Ltd, Pharmaceutical Solutions Industry Ltd., Sichuan Kelun Pharmaceutical Co. Ltd. and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report:

• How has the global large volume parenteral (LVP) market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global large volume parenteral (LVP) market?
• What are the key regional markets?
• What is the breakup of the market based on the type?
• What is the breakup of the market based on the volume?
• What is the breakup of the market based on the application?
• What is the breakup of the market based on the end users?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global large volume parenteral (LVP) market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Large Volume Parenteral (LVP) Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Soft Bag LVP
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Plastic Bottle LVP
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Glass Bottle LVP
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Volume

• 7.1 100 ML - 250 ML
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 250 ML - 500 ML
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 500 ML - 1000 ML
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 1000 ML - 2000 ML
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 2000 ML and More
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by Application

• 8.1 Therapeutic Injections
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Fluid Balance Injections
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Nutritious Injections
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by End Users

• 9.1 Hospitals
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Clinics
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Others
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Albert David Ltd.
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
  • 15.3.2 B. Braun Melsungen AG
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
  • 15.3.3 Baxter International Inc.
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
  • 15.3.4 BML Parenteral Drugs
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 Fresenius Kabi AG
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 SWOT Analysis
  • 15.3.6 Grifols S.A
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
  • 15.3.7 Otsuka Pharmaceutical Co. Ltd
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
  • 15.3.8 Pharmaceutical Solutions Industry Ltd.
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
  • 15.3.9 Sichuan Kelun Pharmaceutical Co., Ltd.
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
  • 15.3.10 Thermo Fisher Scientific Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis